Affiliation:
1. School of Pharmacy, Anhui Medical University, Hefei 230032, China
Abstract
Pancreatic cancer is a prevalent malignant tumor with rising medication resistance and mortality. Due to a dearth of specific and trustworthy biomarkers and therapeutic targets, pancreatic cancer early detection and treatment are still not at their best. Exosomal LncRNAs have been found to be plentiful and persistent within exosomes, and they are capable of functioning whether the exosomes are traveling to close or distant cells. Furthermore, increasing evidence suggests that exosomal LncRNA, identified as an oncogene or tumor suppressor-control the growth, metastasis, and susceptibility of pancreatic cancer to chemotherapy and radiation therapy. Promising prospects for both antitumor targets and diagnostic biomarkers are exosomal LncRNAs. The primary features of exosomal LncRNAs, their biological roles in the onset and progression of pancreatic cancer, and their potential as therapeutic targets and diagnostic molecular markers are outlined in this review.
Funder
Key Technologies Research and Development Program of Anhui Province
Reference124 articles.
1. Molecular Subtypes of Pancreatic Cancer;Collisson;Nat. Rev. Gastroenterol. Hepatol.,2019
2. Cancer Statistics, 2024;Siegel;CA A Cancer J. Clin.,2024
3. Pancreatic Cancer: A Review of Clinical Diagnosis, Epidemiology, Treatment and Outcomes;McGuigan;World J. Gastroenterol.,2018
4. Madadjim, R., An, T., and Cui, J. (2024). MicroRNAs in Pancreatic Cancer: Advances in Biomarker Discovery and Therapeutic Implications. Int. J. Mol. Sci., 25.
5. Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries;Bray;CA A Cancer J. Clin.,2024